ATPγS stalls splicing after B complex formation but prior to spliceosome activation.

RNA

Department of Cellular Biochemistry, MPI for Biophysical Chemistry, D-37077 Göttingen, Germany.

Published: September 2016

The ATP analog ATPγS inhibits pre-mRNA splicing in vitro, but there have been conflicting reports as to which step of splicing is inhibited by this small molecule and its inhibitory mechanism remains unclear. Here we have dissected the effect of ATPγS on pre-mRNA splicing in vitro. Addition of ATPγS to splicing extracts depleted of ATP inhibited both catalytic steps of splicing. At ATPγS concentrations ≥0.5 mM, precatalytic B complexes accumulate, demonstrating a block prior to or during the spliceosome activation stage. Affinity purification of the ATPγS-stalled B complexes (B(ATPγS)) and subsequent characterization of their abundant protein components by 2D gel electrophoresis revealed that B(ATPγS) complexes are compositionally more homogeneous than B complexes previously isolated in the presence of ATP. In particular, they contain little or no Prp19/CDC5L complex proteins, indicating that these proteins are recruited after assembly of the precatalytic spliceosome. Under the electron microscope, B(ATPγS) complexes exhibit a morphology highly similar to B complexes, indicating that the ATPγS-induced block in the transformation of the B to B(act) complex is not due to a major structural defect. Likely mechanisms whereby ATPγS blocks spliceosome assembly at the activation stage, including inhibition of the RNA helicase Brr2, are discussed. Given their more homogeneous composition, B complexes stalled by ATPγS may prove highly useful for both functional and structural analyses of the precatalytic spliceosome and its conversion into an activated B(act) spliceosomal complex.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986889PMC
http://dx.doi.org/10.1261/rna.057810.116DOI Listing

Publication Analysis

Top Keywords

prior spliceosome
8
spliceosome activation
8
pre-mrna splicing
8
splicing vitro
8
activation stage
8
batpγs complexes
8
precatalytic spliceosome
8
atpγs
7
complexes
7
splicing
6

Similar Publications

Article Synopsis
  • The study investigates 11 previously unreported patients with a neurodevelopmental disorder (NDD) caused by genetic changes in the RNU4-2 gene, highlighting the need for better diagnostic approaches as many NDDs remain undiagnosed.
  • The patients, ranging from 13 months to 36 years old, exhibited severe developmental delays, distinct physical features, and other health issues like microcephaly and intrauterine growth retardation.
  • The findings enhance the understanding of RNU4-2 syndrome's phenotypic spectrum, emphasizing the importance of thorough clinical evaluations in identifying and characterizing new syndromes in patients with NDDs.
View Article and Find Full Text PDF
Article Synopsis
  • GSK3326595 is a selective inhibitor of PRMT5 being tested for treating blood cancers like MDS, CMML, and AML, showing promise in preclinical studies by decreasing cancer cell growth and increasing cell death.
  • The study aimed to evaluate the drug's clinical activity, safety, and pharmacokinetics in adults with relapsed myeloid neoplasms, focusing on those who received either 400 or 300 mg daily doses.
  • Out of 30 enrolled patients, 17% achieved clinical benefits, primarily those with specific genetic mutations; common side effects included low platelet counts and fatigue, while the drug demonstrated quick absorption characteristics.
View Article and Find Full Text PDF

RNA exon editing: Splicing the way to treat human diseases.

Mol Ther Nucleic Acids

September 2024

Ascidian Therapeutics, Boston, MA, USA.

RNA exon editing is a therapeutic strategy for correcting disease-causing mutations by inducing -splicing between a synthetic RNA molecule and an endogenous pre-mRNA target, resulting in functionally restored mRNA and protein. This approach enables the replacement of exons at the kilobase scale, addresses multiple mutations with a single therapy, and maintains native gene expression without changes to DNA. For genes larger than 5 kb, RNA exon editors can be delivered in a single vector despite AAV capacity limitations because only mutated exons need to be replaced.

View Article and Find Full Text PDF

Molecular impact of mutations in RNA splicing factors in cancer.

Mol Cell

October 2024

Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

Somatic mutations in genes encoding components of the RNA splicing machinery occur frequently in multiple forms of cancer. The most frequently mutated RNA splicing factors in cancer impact intronic branch site and 3' splice site recognition. These include mutations in the core RNA splicing factor SF3B1 as well as mutations in the U2AF1/2 heterodimeric complex, which recruits the SF3b complex to the 3' splice site.

View Article and Find Full Text PDF

Transcriptomic analysis reveals PC4's participation in thermotolerance of scallop Argopecten irradians irradians by regulating myocardial bioelectric activity.

Comp Biochem Physiol Part D Genomics Proteomics

December 2024

MOE Key Laboratory of Marine Genetics and Breeding, College of Marine Life Sciences, Ocean University of China, 5 Yushan Road, Qingdao 266003, China; Laboratory for Marine Fisheries Science and Food Production Processes, Qingdao Marine Science and Technology Center, Qingdao 266237, China.

Rising ocean temperatures due to global warming pose a significant threat to the bay scallop aquaculture industry. Understanding the mechanisms of thermotolerance in bay scallops is crucial for developing thermotolerant breeds. Our prior research identified Arg0230340.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!